Navigation Links
Signature Therapeutics, Inc., Presents Four Scientific Posters Today at PAINWeek 2013 Meeting

PALO ALTO, Calif., Sept. 5, 2013 /PRNewswire/ -- Signature Therapeutics, Inc., today presented four scientific posters at the PAINWeek 2013 national conference in Las Vegas.  The posters illustrate the company's (i) trypsin-labile, immediate- and extended-release opioid prodrugs that release the parent opioid following oral administration; (ii) results of extended-release prodrugs oxycodone and hydromorphone withstanding tampering and abuse using standard crushing and extracting techniques; and (iii) First-in-man study findings of its trypsin-liable extended-release hydromorphone prodrug.


Every year in the United States prescription opioid abuse is responsible for tens of thousands of deaths and tens of billions of dollars in increased health care costs.  Wes Sterman, President and CEO of Signature Therapeutics, commented, "We believe that our prodrug technology approach creating abuse-deterrent opioid drugs has the potential to greatly impact the public health crisis of prescription drug abuse."

About The Opioid Abuse Challenge

The abuse and misuse of prescription opioid drugs has reached epidemic proportions in the United States. Despite efforts to develop opioid drug formulations that are resistant to tampering, abusers will soon match the advances in pill/tablet formulation technology with new ways to abuse these drugs.  Typical methods of abuse of prescription opioid drugs include inhaling or injecting crushed pills or chewing intact pills.  Current efforts to thwart these modes of abuse, involving improved tablet-formulation technology to make tablets harder to crush and the opioid drug harder to remove from the tablet, provide some increased level of abuse-resistance.  However, Signature Therapeutics' prodrug technology involves creating new molecules that provide very high levels of abuse-resistance based upon the design of the molecules themselves.

About Signature Therapeutics

Signature Therapeutics, Inc. is a development-stage biopharmaceutical company located in Palo Alto, California.  The Company focuses on the discovery and development of a portfolio of novel chemical entities for the potential treatment of neurological disorders.

Signature Therapeutics Contact:

Carey DeRafael

phone: 650-331-4006

SOURCE Signature Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Senator Shares Insight on Florida Physician Dispensing Legislation as First Guest of Progressive Medicals New SignatureSeries
2. Signature Therapeutics Receives BrIDGs Award to Advance Its Abuse-Deterrent Oxycodone, PF614
3. CLAAD Lauds Signature Therapeutics R&D Efforts To Reduce Prescription Drug Abuse
4. Wacoms New DTU-1031 Provides Paperless Electronic Signature Solution for Businesses
5. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
6. PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
7. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
8. Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
9. Autoinjectors to 2018 Devices, Therapeutics, Markets, Strategies and Prospect
10. ADVENTRX Completes Name Change To "Mast Therapeutics, Inc."; New Ticker Symbol: "MSTX"
11. Autoinjectors to 2018 - Devices, Therapeutics, Markets, Strategies and Prospects
Post Your Comments:
(Date:6/26/2016)... VEGAS , June 26, 2016 ... to value-based care operating models within the health care ... enable greater financial efficiency , Deloitte offers a ... the key business issues impacting efficient cost optimization: labor ... , These services facilitate better outcomes and better ...
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... 2016 Research and Markets ... Electronics 2015-2025: Applications, Technologies, Forecasts" report to ... In-Mold Electronics, Smart Skin, Structural Health Monitoring, Composite ... Structural electronics involves electronic and/or electrical components and ... dumb structures such as vehicle bodies or conformally ...
Breaking Medicine Technology:
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from reveals that behind the tendency to set ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
Breaking Medicine News(10 mins):